Drug Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio

January 09, 2024

In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.

Webcasts

Zerion Pharma R&D Day – Dispersome® Drug Formulation Platform

January 08, 2024

Webinar Date/Time: Tue, Jan 30, 2024 9:00 AM EST

Webcasts

Making the Grade: The Importance of Using the Correct Excipient Grade in Drug Products

January 08, 2024

Webinar Date/Time: Thu, Jan 25, 2024 11:00 AM EST

Webcasts

From Technology Selection to Final Drug Product: Material Sparing Approaches for ASD Development

January 08, 2024

Webinar Date/Time: Tue, Jan 30, 2024 11:00 AM EST

DoD Grants Additional Funds to MediWound for Advancement of Non-Surgical Treatment for Field Care Burns

January 05, 2024

MediWound has been granted an additional $6.7 million by the DoD to advance NexoBrid as a non-surgical field care solution for the US military.

Boehringer Ingelheim and Ribo Partner on RNA-based Liver Disease Therapeutics

January 05, 2024

Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH.

AstraZeneca Poised to Acquire Cell Therapy Developer, Gracell, in Deal Valued at $1.2 Billion

January 04, 2024

AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.

Frontrunners in Molecular Glues

January 03, 2024

Novel molecular glues are transforming targeted protein degradation.

Choosing the Right Excipients for MSC and iPSC Therapies

January 03, 2024

Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.

Replay Signs Exclusive Licensing Agreements with NIH and Miltenyi Biotec for Cell Therapy Development and Manufacturing

December 29, 2023

Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec.